NEW YORK, NY / ACCESSWIRE / May 31, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

FGEN Shareholders Click Here: https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=16385&wire=1
DOX Shareholders Click Here: https://www.zlk.com/pslra-1/amdocs-limited-loss-submission-form?prid=16385&wire=1
CCIV Shareholders Click Here: https://www.zlk.com/pslra-1/churchill-capital-corp-iv-information-request-form?prid=16385&wire=1

* ADDITIONAL INFORMATION BELOW *

FibroGen, Inc. (NASDAQ:FGEN)

FGEN Lawsuit on behalf of: investors who purchased October 18, 2017 - April 6, 2021
Lead Plaintiff Deadline : June 11, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=16385&wire=1

According to the filed complaint, during the class period, FibroGen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Amdocs Limited (NASDAQ:DOX)

DOX Lawsuit on behalf of: investors who purchased December 13, 2016 - March 30, 2021
Lead Plaintiff Deadline : June 8, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/amdocs-limited-loss-submission-form?prid=16385&wire=1

According to the filed complaint, during the class period, Amdocs Limited made materially false and/or misleading statements and/or failed to disclose that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs' reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Churchill Capital Corp IV (NYSE:CCIV)

CCIV Lawsuit on behalf of: investors who purchased January 11, 2021 - February 22, 2021
Lead Plaintiff Deadline : July 6, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/churchill-capital-corp-iv-information-request-form?prid=16385&wire=1

According to the filed complaint, during the class period, Churchill Capital Corp IV made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com:
https://www.accesswire.com/649822/CLASS-ACTION-UPDATE-for-FGEN-DOX-and-CCIV-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders